Galectin Therapeutics (GALT) Misses Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Ennis (EBF) Reports In-Line Q1 EPS
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
